ATP Synthesis-IN-3

ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis[1].

Product Specifications

CAS Number

[3032416-36-4]

UNSPSC

12352005

Target

ATP Synthase; PKA

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/atp-synthesis-in-3.html

Solubility

10 mM in DMSO

Smiles

CN1CCN(C2=CC=C(NC3=NC(N4CCOCC4)=C5C(C(C6=CC=CC=C6)=NN5CC7=CC=C(C=C7)OC)=C3)C=C2)CC1

Molecular Formula

C35H39N7O2

Molecular Weight

589.73

References & Citations

[1]Nikolaou PE et al. Hydrolytic Activity of Mitochondrial F1FO-ATP Synthase as a Target for Myocardial Ischemia-Reperfusion Injury: Discovery and In Vitro and In Vivo Evaluation of Novel Inhibitors. J Med Chem. 2023 Nov 23;66 (22) :15115-15140.